Advertisement

DNA Topoisomerases as Targets for Antibacterial Agents

  • Hiroshi Hiasa
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1703)

Abstract

DNA topoisomerases are proven therapeutic targets of antibacterial agents. Quinolones, especially fluoroquinolones, are the most successful topoisomerase-targeting antibacterial drugs. These drugs target type IIA topoisomerases in bacteria. Recent structural and biochemical studies on fluoroquinolones have provided the molecular basis for both their mechanism of action, as well as the molecular basis of bacterial resistance. Due to the development of drug resistance, including fluoroquinolone resistance, among bacterial pathogens, there is an urgent need to discover novel antibacterial agents. Recent advances in topoisomerase inhibitors may lead to the development of novel antibacterial drugs that are effective against fluoroquinolone-resistant pathogens. They include type IIA topoisomerase inhibitors that either interact with the GyrB/ParE subunit or form nick-containing ternary complexes. In addition, several topoisomerase I inhibitors have recently been identified. Thus, DNA topoisomerases remain important targets of antibacterial agents.

Key words

Aminocoumarin Antibacterial drugs DNA gyrase Fluoroquinolone Topoisomerase I Topoisomerase IV Topoisomerase poison 

Notes

Acknowledgments

I would like to thank Lisa Oppegard for her contribution and critical comments on the manuscript, Fang Li for invaluable discussion, and Justine Delgado for preparation of Fig. 1 and critical comments on the manuscript. Studies from my laboratory were supported in part by National Institutes of Health grants GM59465, AI087671, and a fellowship from SmithKline Beecham Pharmaceuticals.

References

  1. 1.
    Watson JD, Crick FH (1953) Genetical implications of the structure of deoxyribonucleic acid. Nature 171:964–967CrossRefPubMedGoogle Scholar
  2. 2.
    Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413CrossRefPubMedGoogle Scholar
  3. 3.
    Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440CrossRefPubMedGoogle Scholar
  4. 4.
    Nitiss JL (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9:327–337CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Vos SM, Tretter EM, Schmidt BH, Berger JM (2011) All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12:827–841CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bush NG, Evans-Roberts K, Maxwell A (2015) DNA topoisomerases. EcoSal Plus. https://doi.org/10.1128/ecosalplus.ESP-0010-2014
  7. 7.
    Stupina VA, Wang JC (2005) Viability of Escherichia coli topA mutants lacking DNA topoisomerase I. J Biol Chem 280:355–360CrossRefPubMedGoogle Scholar
  8. 8.
    Jeong KS, Xie Y, Hiasa H, Khodursky AB (2006) Analysis of pleiotropic transcriptional profiles: a case study of DNA gyrase inhibition. PLoS Genet 2:e152CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Forterre P (2006) DNA topoisomerase V: a new fold of mysterious origin. Trends Biotechnol 24:245–247CrossRefPubMedGoogle Scholar
  10. 10.
    Bergerat A, Gadelle D, Forterre P (1994) Purification of a DNA topoisomerase II from the hyperthermophilic archaeon Sulfolobus shibatae. A thermostable enzyme with both bacterial and eucaryal features. J Biol Chem 269:27663–27669PubMedGoogle Scholar
  11. 11.
    Malik SB, Ramesh MA, Hulstrand AM, Logsdon JM Jr (2007) Protist homologs of the meiotic Spo11 gene and topoisomerase VI reveal an evolutionary history of gene duplication and lineage-specific loss. Mol Biol Evol 24:2827–2841CrossRefPubMedGoogle Scholar
  12. 12.
    Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92:479–497CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8:82–95CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mayer C, Janin YL (2014) Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem Rev 114:2313–2342CrossRefPubMedGoogle Scholar
  15. 15.
    Ehmann DE, Lahiri SD (2014) Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. Curr Opin Pharmacol 18:76–83CrossRefPubMedGoogle Scholar
  16. 16.
    Gellert M, Mizuuchi K, O'Dea MH, Nash HA (1976) DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A 73:3872–3876CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gellert M, O'Dea MH, Itoh T, Tomizawa J (1976) Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A 73:4474–4478CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR (1977) Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A 74:4767–4771CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa J (1977) Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 74:4772–4776CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kato J, Suzuki H, Ikeda H (1992) Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem 267:25676–25684PubMedGoogle Scholar
  21. 21.
    Peng H, Marians KJ (1993) Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem 268:24481–24490PubMedGoogle Scholar
  22. 22.
    Redgrave L, Sutton S, Webber M, Piddock L (2012) Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 22:438–445CrossRefGoogle Scholar
  23. 23.
    Dalhoff A (2012) Resistance surveillance studies: a multifaceted problem – the fluoroquinolone example. Infection 40:239–262CrossRefPubMedGoogle Scholar
  24. 24.
    Tse-Dinh YC (2015) Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics. Future Med Chem 7:459–471CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Levine C, Hiasa H, Marians KJ (1998) DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1400:29–43CrossRefPubMedGoogle Scholar
  26. 26.
    Wang JC, Becherer K (1983) Cloning of the gene topA encoding for DNA topoisomerase I and the physical mapping of the cysB-topA-trp region of Escherichia coli. Nucleic Acids Res 11:1773–1790CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    DiGate RJ, Marians KJ (1989) Molecular cloning and DNA sequence analysis of Escherichia coli topB, the gene encoding topoisomerase III. J Biol Chem 264:17924–17930PubMedGoogle Scholar
  28. 28.
    Mizuuchi K, O'Dea MH, Gellert M (1978) DNA gyrase: subunit structure and ATPase activity of the purified enzyme. Proc Natl Acad Sci U S A 75:5960–5963CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H (1990) New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393–404CrossRefPubMedGoogle Scholar
  30. 30.
    Bates AD, Maxwell A (1997) DNA topology: topoisomerases keep it simple. Curr Biol 7:R778–R781CrossRefPubMedGoogle Scholar
  31. 31.
    Wang JC, Liu LF (1990) DNA replication: topological aspects and the roles of DNA topoisomerases. In: Cozzarelli NR, Wang JC (eds) DNA topology and its biological effects. Cold Spring Harbor, Cold Spring Harbor LaboratoryGoogle Scholar
  32. 32.
    Cairns J (1963) The bacterial chromosome and its manner of replication as seen by autoradiography. J Mol Biol 6:208–213CrossRefPubMedGoogle Scholar
  33. 33.
    Hiasa H, Marians KJ (1996) Two distinct modes of strand unlinking during θ-type DNA replication. J Biol Chem 271:21529–21535CrossRefPubMedGoogle Scholar
  34. 34.
    Peter BJ, Ullsperger C, Hiasa H, Marians KJ, Cozzarelli NR (1998) The structure of supercoiled intermediates in DNA replication. Cell 94:819–827CrossRefPubMedGoogle Scholar
  35. 35.
    Ullsperger C, Vologodskii A, Cozzarelli NR (1995) Unlinking of DNA by topoisomerases during DNA replication. In: Lilly D, Eckstein F (eds) Nucleic acids and molecular biology, vol 9. Springer-Verlag, Berlin, pp 115–142CrossRefGoogle Scholar
  36. 36.
    Hiasa H, Marians KJ (1994) Topoisomerase III, but not topoisomerase I, can support nascent chain elongation during theta-type DNA replication. J Biol Chem 269:32655–32659PubMedGoogle Scholar
  37. 37.
    Bliska JB, Cozzarelli NR (1987) Use of site-specific recombination as a probe of DNA structure and metabolism in vivo. J Mol Biol 194:205–218CrossRefPubMedGoogle Scholar
  38. 38.
    Hiasa H, DiGate RJ, Marians KJ (1994) Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro. J Biol Chem 269:2093–2099PubMedGoogle Scholar
  39. 39.
    Hiasa H, Marians KJ (1994) Topoisomerase IV can support oriC DNA replication in vitro. J Biol Chem 269:16371–16375PubMedGoogle Scholar
  40. 40.
    Zechiedrich EL, Khodursky AB, Cozzarelli NR (1997) Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli. Genes Dev 11:2580–2592CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544CrossRefPubMedGoogle Scholar
  42. 42.
    Aubry A, Fisher LM, Jarlier V, Cambau E (2006) First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun 348:158–165CrossRefPubMedGoogle Scholar
  43. 43.
    Li SM, Heide L (2005) The biosynthetic gene clusters of aminocoumarin antibiotics. Curr Med Chem 12:419–427CrossRefPubMedGoogle Scholar
  44. 44.
    Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR (1978) Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A 75:4838–4842CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Maxwell A, Lawson DM (2003) The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 3:283–303CrossRefPubMedGoogle Scholar
  46. 46.
    Azam MA, Thathan J, Jubie S (2015) Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: a review. Bioorg Chem 62:41–63CrossRefPubMedGoogle Scholar
  47. 47.
    Schimana J, Fiedler HP, Groth I, Süssmuth R, Beil W et al (2000) Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tü 6040. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot 53:779–787CrossRefPubMedGoogle Scholar
  48. 48.
    Theobald U, Schimana J, Fiedler HP (2000) Microbial growth and production kinetics of Streptomyces antibioticus Tü 6040. Antonie Van Leeuwenhoek 78:307–313CrossRefPubMedGoogle Scholar
  49. 49.
    Holzenkämpfer M, Walker M, Zeeck A, Schimana J, Fiedler HP (2002) Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tü 6040 II. Structure elucidation and biosynthesis. J Antibiot 55:301–307CrossRefPubMedGoogle Scholar
  50. 50.
    Flatman RH, Howells AJ, Heide L, Fiedler HP, Maxwell A (2005) Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action. Antimicrob Agents Chemother 49:1093–1100CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Oppegard LM, Hamann BL, Streck KR, Ellis KC, Fiedler HP et al (2009) In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother 53:2110–2119CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hearnshaw SJ, Edwards MJ, Stevenson CE, Lawson DM, Maxwell A (2014) A new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. J Mol Biol 426:2023–2033CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Tsao YP, Russo A, Nyamuswa G, Silber R, Liu LF (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53:5908–5914PubMedGoogle Scholar
  54. 54.
    Hiasa H, Yousef DO, Marians KJ (1996) DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J Biol Chem 271:26424–26429CrossRefPubMedGoogle Scholar
  55. 55.
    Hong G, Kreuzer KN (2000) An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo. Mol Cell Biol 20:594–603CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Lucas I, Germe T, Chevrier-Miller M, Hyrien O (2001) Topoisomerase II can unlink replicating DNA by precatenane removal. EMBO J 20:6509–6519CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A et al (2009) Quinolones: action and resistance updated. Curr Top Med Chem 9:981–998CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Goss WA, Deitz WH, Cook TM (1965) Mechanism of action of nalidixic acid on Escherichia coli II. Inhibition of deoxyribonucleic acid synthesis. J Bacteriol 89:1068–1074PubMedPubMedCentralGoogle Scholar
  59. 59.
    Emmerson AM, Jones AM (2003) The quinolones: decades of development and use. J Antimicrob Chemother 51:13–20CrossRefPubMedGoogle Scholar
  60. 60.
    Ito A, Hirai K, Inoue M, Koga H, Suzue S et al (1980) In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother 17:103–108CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Kreuzer KN, Cozzarelli NR (1979) Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit a: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J Bacteriol 140:424–435PubMedPubMedCentralGoogle Scholar
  62. 62.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J et al (1994) Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 13:641–653CrossRefPubMedGoogle Scholar
  63. 63.
    Khodursky AB, Zechiedrich EL, Cozzarelli NR (1995) Topoisomerase IV is a target of quinolones in Esherichia coli. Proc Natl Acad Sci U S A 92:11801–11805CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34:1271–1272CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Khodursky AB, Cozzarelli NR (1998) The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 273:27668–27677CrossRefPubMedGoogle Scholar
  66. 66.
    Shea ME, Hiasa H (2000) Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes. J Biol Chem 275:14649–14658CrossRefPubMedGoogle Scholar
  67. 67.
    Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A et al (1997) Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903–906CrossRefPubMedGoogle Scholar
  68. 68.
    Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J et al (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17:1152–1153CrossRefPubMedGoogle Scholar
  69. 69.
    Laponogov I, Pan XS, Veselkov DA, McAuley DA, Fisher LM et al (2010) Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5:e11338CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Blower TR, Williamson BH, Kerns RJ, Berger JM (2016) Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:1706–1713CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565–1574CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Pfeiffer ES, Hiasa H (2004) Replacement of ParC alpha4 helix with that of GyrA increases the stability and cytotoxicity of topoisomerase IV-quinolone-DNA ternary complexes. Antimicrob Agents Chemother 48:608–611CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Hiasa H, Shea ME (2000) DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex. J Biol Chem 275:34780–34786CrossRefPubMedGoogle Scholar
  74. 74.
    Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647–1650CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Pan XS, Gould KA, Fisher LM (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother 53:3822–3831CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Wang J, Yu P, Lin TC, Konigsberg WH, Steitz TA (1996) Crystal structures of an NH2-terminal fragment of T4 DNA polymerase and its complexes with single-stranded DNA and with divalent metal ions. Biochemistry 35:8110–8119CrossRefPubMedGoogle Scholar
  77. 77.
    West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R et al (2000) Mutagenesis of E477 or K505 in the B' domain of human topoisomerase IIβ increases the requirement for magnesium ions during strand passage. Biochemistry 39:1223–1233CrossRefPubMedGoogle Scholar
  78. 78.
    Pitts SL, Liou GF, Mitchenall LA, Burgin AB, Maxwell A et al (2011) Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Nucleic Acids Res 39:4808–4817CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Noble CG, Maxwell A (2002) The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: a proposed two metal-ion mechanism. J Mol Biol 318:361–371CrossRefPubMedGoogle Scholar
  80. 80.
    Deweese JE, Burgin JE, Osheroff N (2008) Human topoisomerase IIα uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res 36:4883–4893CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Oppegard LM, Schwanz HA, Towle TR, Kerns RJ, Hiasa H (2016) Fluoroquinolones stimulate the DNA cleavage activity of topoisomerase IV by promoting the binding of Mg(2+) to the second metal binding site. Biochim Biophys Acta 1860:569–575CrossRefPubMedGoogle Scholar
  82. 82.
    Marians KJ, Hiasa H (1997) Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem 272:9401–9409CrossRefPubMedGoogle Scholar
  83. 83.
    German N, Malik M, Rosen JD, Drlica K, Kerns RJ (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones. Antimicrob Agents Chemother 52:3915–3921CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Malik M, Marks KR, Mustaev A, Zhao X, Chavda K et al (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother 55:2335–2343CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Drlica K, Mustaev A, Towle TR, Luan G, Kerns RJ et al (2014) Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem Biol 9:2895–2904CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR et al (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940CrossRefPubMedGoogle Scholar
  87. 87.
    Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP et al (2008) Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother 52:2806–2812CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Chan PF, Srikannathasan V, Huang J, Cui H, Fosberry AP et al (2015) Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. Nat Commun 6:10048CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Miles TJ, Barfoot C, Brooks G, Brown P, Chen D et al (2011) Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett 21:7483–7488CrossRefPubMedGoogle Scholar
  90. 90.
    Miles TJ, Axten JM, Barfoot C, Brooks G, Brown P et al (2011) Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett 21:7489–7495CrossRefPubMedGoogle Scholar
  91. 91.
    Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS et al (2013) Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Bioorg Med Chem Lett 23:5437–5441CrossRefPubMedGoogle Scholar
  92. 92.
    Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS et al (2016) Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases. Bioorg Med Chem Lett 26:2464–2469CrossRefPubMedGoogle Scholar
  93. 93.
    Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN (2014) Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol 52:2629–2632CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J et al (2014) High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585–5588CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC et al (2015) In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59:467–474CrossRefPubMedGoogle Scholar
  96. 96.
    Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE et al (2015) Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59:1478–1486CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Godbole AA, Ahmed W, Bhat RS, Bradley EK, Ekins S et al (2015) Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors. Antimicrob Agents Chemother 59:1549–1557CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Sandhaus S, Annamalai T, Welmaker G, Houghten RA, Paz C et al (2016) Small-molecule inhibitors targeting topoisomerase I as novel antituberculosis agents. Antimicrob Agents Chemother 60:4028–4036CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations